News

In 2000, troglitazone (GlaxoSmithKline’s Rezulin) was withdrawn from the market due to severe liver toxicity with an unknown mechanism. Troglitazone and other currently marketed drugs, such as rosiglitazone

Intellectual property filings have been made to further strengthen the company’s patent position for its nerve cell targeted protease inhibitor platform technology. More specifically, CepTor has filed to

The primary objective of the phase II clinical trial is to evaluate the safety and tolerability of multiple doses of PRX-00023 in patients with moderate to severe generalized

The two compounds are AL-108, Allon’s lead product candidate currently being evaluated in human clinical trials as a treatment for Alzheimer’s disease, and AL-209, one of Allon’s preclinical-stage

Labopharm is leveraging regulatory approval of the product in France, which will serve as first approval status in a major regulatory jurisdiction, to facilitate the regulatory approval process

The new target gene is called methylenetetrahydrofolate reductase, or MTHFR. The McGill University Health Centre (MUHC) researchers were able to inhibit the function of the gene by creating

The study showed that the improvements in cardiovascular risk factors achieved with rimonabant 20mg/day at the end of the first year of treatment were maintained in the second

The first US Department of Defense (DoD) contract, for $2.5 million, will support the second year of Diversa’s program for rapid antibody-based biological countermeasures (RAbBC). The second contract,

The ascending-dose, placebo controlled trial will evaluate the safety as well as the pharmacokinetic and pharmacodynamic profile of DG041, DeCode’s novel, first-in-class, orally-administered small molecule. In preclinical studies,